Mirati's SAPPHIRE trial in NSCLC terminated, results posted on ClinicalTrials.govSep 30Trial updateBristol Myers Squibbnivolumab
BMS trials update: CheckMate-67T posts results; two studies added for irAE care and lung screeningSep 25Weekly roundup, 4 itemsBristol Myers Squibbclarithromycin
BMS logs three FDA label approvals and posts results for melanoma combo trialSep 2Weekly roundup, 5 itemsadagrasibBristol Myers Squibb
BMS registers new deucravacitinib continuation study; prior week's trial results still standAug 27Weekly roundup, 5 itemsBristol Myers Squibbdeucravacitinib
NovaBridge reports H1 2026 results, targets year-end Phase 3 start for givastomigAug 20PeopleNovaBridge Biosciences
Replimune's TUDRIQEV wins FDA accelerated approval, launch set within 60 daysAug 14Quarterly updateReplimune, Inc.
BMS posts JAKARTA Phase 3 results, updates Opdivo label, registers golcadomide renal studyAug 13Weekly roundup, 4 itemsBristol Myers Squibbgolcadomide
Perspective Therapeutics reports 2Q 2026 results, advances toward VMT-α-NET Phase 3Aug 10Clinical readoutPerspective Therapeutics
Replimune's $150 million offering formalized in prospectus supplement filed with SECAug 10FinancingReplimune, Inc.
FDA grants accelerated approval to Replimune's TUDRIQEV plus nivolumab for melanomaAug 6Regulatory decisionnivolumabReplimune, Inc.
Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer dataAug 5Quarterly updateXencor, Inc.XMAB819
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
FDA advisory committee backs RP1 efficacy data in advanced melanoma, 10-3Jul 30Regulatory milestoneReplimune, Inc.
Bicycle Therapeutics reports Q2 2026 pipeline progress, cash into 2030Jul 30Quarterly updateBicycle Therapeutics Plc
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarterJul 29Quarterly updateCorcept Therapeuticsmifepristone
Scancell to merge with Neuphoria and list on Nasdaq, plans up to $89 million financingJul 23PartnershipNeuphoria Therapeutics Inc.
BMS trials post results across lung cancer, sarcoma, myelofibrosis; new stroke study opensJul 17Weekly roundup, 5 itemsBristol Myers Squibblisocabtagene maraleucel
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin
Replimune's RP1 BLA resubmission accepted by FDA; adcomm expected late JulyJun 29Quarterly updateReplimune, Inc.
Sign inSign in